Abstract

Patients with chronic kidney disease (CKD) and end-stage renal disease suffer from increased cardiovascular events and cardiac mortality. Prior studies have demonstrated that a portion of this enhanced risk can be attributed to the accumulation of microbiota-derived toxic metabolites, with most studies focusing on the sulfonated form of p-cresol (PCS). However, unconjugated p-cresol (uPC) itself was never assessed due to rapid and extensive first-pass metabolism that results in negligible serum concentrations of uPC. These reports thus failed to consider the host exposure to uPC prior to hepatic metabolism. In the current study, not only did we measure the effect of altering the intestinal microbiota on lipid accumulation in coronary arteries, but we also examined macrophage lipid uptake and handling pathways in response to uPC. We found that atherosclerosis-prone mice fed a high-fat diet exhibited significantly higher coronary artery lipid deposits upon receiving fecal material from CKD mice. Furthermore, treatment with uPC increased total cholesterol, triglycerides, and hepatic and aortic fatty deposits in non-CKD mice. Studies employing an in vitro macrophage model demonstrated that uPC exposure increased apoptosis whereas PCS did not. Additionally, uPC exhibited higher potency than PCS to stimulate LDL uptake and only uPC induced endocytosis- and pinocytosis-related genes. Pharmacological inhibition of varying cholesterol influx and efflux systems indicated that uPC increased macrophage LDL uptake by activating macropinocytosis. Overall, these findings indicate that uPC itself had a distinct effect on macrophage biology that might have contributed to increased cardiovascular risk in patients with CKD.

Highlights

  • Interventions aimed at controlling traditional cardiovascular disease (CVD) risk factors in patients with chronic kidney disease (CKD) have proven less effective despite of treatment advances for hypertension, diabetes, and dyslipidemia [1,2,3,4]

  • We aimed to investigate the causality between CKD-associated dysbiosis (CKD-AD) and increased CVD risk by administering CKD fecal material to atherosclerosis-prone apolipoprotein E–knockout (ApoE–/–) mice [54] to determine if this would result in worsened coronary atherosclerotic lesions

  • We demonstrate that CKD-AD accelerated lipid deposits in coronary arteries of ApoE–/– mice fed a HFD, further supporting the role CKD-AD has in the development and risk of CVD

Read more

Summary

Introduction

Interventions aimed at controlling traditional cardiovascular disease (CVD) risk factors in patients with chronic kidney disease (CKD) have proven less effective despite of treatment advances for hypertension, diabetes, and dyslipidemia [1,2,3,4]. Nontraditional risk factors, such as inflammation, oxidative stress, and endothelial dysfunction, have been shown to play a key part in the development and outcome of CVD [10,11,12,13]. One such component is CKD-associated dysbiosis (CKD-AD), which is the dysfunction within the microbiome-host relationship brought on by numerous factors in CKD [14, 15]. There is an ever-expanding research base supporting an altered microbiome in CKD, and numerous studies have delineated several pathways whereby CKD progression promotes microbiome dysbiosis and vice versa [8, 16,17,18,19,20,21,22,23,24,25]

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call